Press
Releases

May 26, 2026 Jade Biosciences Announces First Participant Dosed in First-in-Human Phase 1 Clinical Trial of JADE201, a Novel Half-Life Extended Afucosylated Anti-BAFF Receptor Monoclonal Antibody May 26, 2026 Jade Biosciences Announces First Participant Dosed in Phase 2 JUNIPER Clinical Trial of JADE101 in IgA Nephropathy May 7, 2026 Jade Biosciences Reports First Quarter 2026 Financial Results and Provides Corporate Update April 23, 2026 Jade Biosciences Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) April 22, 2026 Jade Biosciences Appoints Edward R. Conner, M.D., as Chief Medical Officer March 6, 2026 Jade Biosciences Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Corporate Update February 11, 2026 Jade Biosciences to Participate in Upcoming Conferences January 5, 2026 Jade Biosciences Outlines Key 2026 Objectives and Strategy to Advance Pipeline of Potentially Best-in-Class Monoclonal Antibodies Across Multiple Autoimmune Diseases Ahead of the 44th Annual J.P. Morgan Healthcare Conference December 15, 2025 Jade Biosciences Announces $45 Million Private Placement November 13, 2025 Jade Biosciences Reports Third Quarter 2025 Financial Results and Provides Corporate Update